AbbVie Wins U.S. Approval for Endometriosis Pain Treatment
- Elagolix allowed for use by women with gynecological disorder
- Orilissa could be next big hit for drugmaker after Humira
This article is for subscribers only.
AbbVie Inc. won U.S. approval for an oral medicine that treats pain caused by the gynecological disorder endometriosis, a step toward giving the maker of the blockbuster arthritis treatment Humira another potential billion-dollar sales hit.
The Food and Drug Administration has approved elagolix to treat pain associated with endometriosis, a common condition in which the tissue that lines the uterus grows in other parts of the body. It’s the first such treatment approved in more than a decade, the company said Tuesday in a statement. Marketed under the brand name Orilissa, the medicine should be available in pharmacies at the beginning of August, the drugmaker said.